Clinical Trials in Philadelphia

Showing 4581-4600 of 15,860 trials

Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

NCT03687242

This is a Phase 2 study of SPR001 for the treatment of classic CAH that will provide 12 weeks of open-label treatment to eligible subjects.

Congenital Adrenal HyperplasiaCAH - Congenital Adrenal HyperplasiaCAH - 21-Hydroxylase Deficiency

Spruce Biosciences11 participantsStarted Sep 2018

Orange, California, United States • San Diego, California, United States • Atlanta, Georgia, United States +5 more locations

COMPLETEDPhase 2< 1 mile

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03153111

This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease. The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these patients.

Heart Failure With Preserved Ejection Fraction

Actelion143 participantsStarted Jul 2017

Phoenix, Arizona, United States • Beverly Hills, California, United States • San Diego, California, United States +92 more locations

Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Find Trials by Condition in Philadelphia

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care

XEN1101 for Major Depressive Disorder

Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

MOTIV BTK Randomized Controlled Trial